CH · biotech · immunology · thymus regeneration
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Seed · Jan 2026 · $13M
Boehringer Ingelheim Venture Fund lead, High-Tech Gründerfonds, Carma Fund, EOS BioInnovation, JFG Life Sciences Foundation of the University of Basel, LifeSpan Vision Ventures, Zurich Cantonal Bank
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.